Century Therapeutics
IPSC
56 hedge funds and large institutions have $183M invested in Century Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
8% more funds holding
Funds holding: 52 → 56 (+4)
0.69% less ownership
Funds ownership: 37.66% → 36.97% (-0.69%)
34% less capital invested
Capital invested by funds: $279M → $183M (-$96.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.73M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$855K |
| 4 |
Millennium Management
New York
|
+$594K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$3.91M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.54M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$723K |
| 5 |
D.E. Shaw & Co
New York
|
-$282K |
IPSC Hedge Fund Activity: Q2 2022 in Review
56 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q2 2022, worth a combined $183M — down 34% from $279M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IPSC positions and 3 closed out — a net gain of 6 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $2.73M. The largest seller was Fidelity Investments, cutting an estimated $6.4M.
- 56 institutional investors held Century Therapeutics (IPSC) as of Q2 2022, up from 52 in Q1 2022.
- Funds reported $183M of Century Therapeutics stock for Q2 2022, down 34% quarter-over-quarter.
- 9 funds opened new Century Therapeutics positions in Q2 2022 and 3 closed out, a net change of +6 holders.
- The largest Century Therapeutics buyer in Q2 2022 was BlackRock, an estimated $2.73M added.
- The largest Century Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $6.4M sold.
Based on aggregated 13F filings for Q2 2022.